CD44 and familial pancreatic carcinoma: While previous studies have explored HA-displaying nanosystems in the treatment of other cancers or diseases [11,26,27,28,29], the specific effects of CS MW together with the use of active targeting via HA-CD44 interactions on delivery efficiency and gene knockdown in pancreatic cancer have not been previously reported, making our approach unique.